Cargando…
Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments
Bladder cancer is the sixth most common malignancy in the United States and 70% of cases are non-muscle invasive at the time of diagnosis. Effective treatment is crucial to prevent progression, which occurs in about 30% of patients. The American Urological Association (AUA) guidelines recommend trea...
Autores principales: | Goldberg, Ilana P., Lichtbroun, Benjamin, Singer, Eric A., Ghodoussipour, Saum |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431226/ https://www.ncbi.nlm.nih.gov/pubmed/36051251 |
Ejemplares similares
-
Examining the Role of Microbiota-Centered Interventions in Cancer
Therapeutics: Applications for Urothelial Carcinoma
por: Drobner, Jake C., et al.
Publicado: (2023) -
The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer
por: Cahill, Ellen M., et al.
Publicado: (2022) -
Does Time to Adjuvant Chemotherapy after Radical Cystectomy Affect Survival in Muscle Invasive Bladder Cancer? A Systematic Review
por: Kronstedt, Shane, et al.
Publicado: (2022) -
Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer: Current Techniques and Future Trends
por: Shalata, Aya T., et al.
Publicado: (2022) -
Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise
por: Darwiche, Fadi, et al.
Publicado: (2015)